Literature DB >> 19328496

Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration.

Daisuke Soma1, Joji Kitayama, Hironori Ishigami, Shoichi Kaisaki, Hirokazu Nagawa.   

Abstract

PURPOSE: Paclitaxel is considered to be suitable for disseminated cancer in the peritoneal cavity because of its high molecular weight and lipophilic characteristics. However, the difference in pharmacokinetics of paclitaxel after intraperitoneal (i.p.) and intravenous (i.v.) administration is not fully defined. Here, we investigated the tissue concentration of paclitaxel in various organs at various time points after i.p. or i.v. administration.
METHODS: Paclitaxel (5 mg/kg) was administrated in an ear vein or in the abdominal cavity of rabbits. At 0.5, 6, 24, and 48 h after administration, the rabbits were sacrificed, and organs as well as peripheral blood were harvested. The serum and tissue concentrations of paclitaxel were measured by HPLC procedure. RESULT: The concentration of paclitaxel was high in the i.v. group at 0.5 h, whereas it was significantly higher in the i.p. group at 6 and 24 h. The AUC (area under the curve) was markedly higher in the omentum, mesenteric lymph nodes as well as ovary and stomach in the i.p. group.
CONCLUSION: Compared with i.v. administration, paclitaxel concentration was maintained at a high level in the whole body by i.p. administration. Repeated i.p. paclitaxel can produce more marked clinical effects than i.v. administration for metastatic lymph nodes and primary lesions as well as peritoneal dissemination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19328496     DOI: 10.1016/j.jss.2008.06.049

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  14 in total

Review 1.  Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.

Authors:  Daisuke Kobayashi; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2016-11-01       Impact factor: 7.370

2.  High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.

Authors:  Federico Coccolini; Fabio Acocella; Lavinia Morosi; Stefano Brizzola; Matteo Ghiringhelli; Marco Ceresoli; Enrico Davoli; Luca Ansaloni; Maurizio D'Incalci; Massimo Zucchetti
Journal:  Pharm Res       Date:  2017-02-28       Impact factor: 4.200

3.  Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics.

Authors:  James D Orth; Rainer H Kohler; Floris Foijer; Peter K Sorger; Ralph Weissleder; Timothy J Mitchison
Journal:  Cancer Res       Date:  2011-06-28       Impact factor: 12.701

Review 4.  Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Shigenobu Emoto; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-02-01       Impact factor: 2.549

Review 5.  Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects.

Authors:  Paul H Sugarbaker
Journal:  J Gastrointest Oncol       Date:  2021-04

6.  Vasodilatation in the rat dorsal hindpaw induced by activation of sensory neurons is reduced by paclitaxel.

Authors:  N G Gracias; T R Cummins; M R Kelley; D P Basile; T Iqbal; M R Vasko
Journal:  Neurotoxicology       Date:  2010-10-07       Impact factor: 4.294

7.  Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.

Authors:  Lawson Eng; Irada Ibrahim-zada; Hamdi Jarjanazi; Sevtap Savas; Mehran Meschian; Kathleen I Pritchard; Hilmi Ozcelik
Journal:  BMC Med Genomics       Date:  2011-02-11       Impact factor: 3.063

8.  Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; Winston Liauw; David Lawson Morris
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

Review 9.  Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes.

Authors:  Hironori Yamaguchi; Joji Kitayama; Hironori Ishigami; Shinsuke Kazama; Hiroaki Nozawa; Kazushige Kawai; Keisuke Hata; Tomomichi Kiyomatsu; Toshiaki Tanaka; Junichiro Tanaka; Takeshi Nishikawa; Kensuke Otani; Koji Yasuda; Soichiro Ishihara; Eiji Sunami; Toshiaki Watanabe
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

10.  Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination.

Authors:  Susumu Hama; Takayuki Nishi; Eitaro Isono; Shoko Itakura; Yutaka Yoshikawa; Akinori Nishimoto; Satoko Suzuki; Naoko Kirimura; Hiroaki Todo; Kentaro Kogure
Journal:  Cancer Sci       Date:  2022-03-31       Impact factor: 6.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.